Inhibikase Therapeutics Inc (IKT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $213.21M
Last updated: Nov 17, 2026 at 11:06 AM ET
Inhibikase Therapeutics Inc (IKT) Earnings: Report Dates and Results
Inhibikase Therapeutics (IKT) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Inhibikase Therapeutics reported EPS of -$0.10, above the -$0.11 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
IKT has an expected report date of Mar 24, 2027.
IKT Earnings Call
The latest IKT earnings call transcript on file is labeled 2024Q2.
Read the 2024Q2 transcriptEarnings History
Of the 22 quarters below that had an estimate, IKT beat 9, missed 11 and matched 2. The widest gap in the table came in the quarter ended Dec 31, 2024, when EPS landed 101.73% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.10 | -$0.11 | -$0.16 - -$0.11 | +9.09% | Beat | N/A | 4 | 0 up, 1 down | Nov 10, 2026 | N/A |
| Jun 30, 2026 | -$0.11 | -$0.09 | -$0.10 - -$0.09 | -22.22% | Miss | N/A | 3 | 1 up, 0 down | Aug 11, 2026 | N/A |
| Mar 31, 2026 | -$0.10 | -$0.09 | -$0.09 - -$0.09 | -5.67% | Miss | N/A | 1 | 0 up, 0 down | May 12, 2026 | N/A |
| Dec 31, 2025 | -$0.09 | -$0.12 | -$0.13 - -$0.12 | +25.00% | Beat | N/A | 2 | 1 up, 0 down | Mar 26, 2026 | N/A |
| Sep 30, 2025 | -$0.13 | -$0.13 | -$0.13 - -$0.13 | 0.00% | In line | N/A | 2 | 1 up, 0 down | Nov 14, 2025 | N/A |
| Jun 30, 2025 | -$0.11 | -$0.08 | N/A | -37.50% | Miss | N/A | N/A | 0 up, 0 down | Aug 14, 2025 | N/A |
| Mar 31, 2025 | -$0.15 | -$0.09 | N/A | -66.67% | Miss | N/A | N/A | 0 up, 0 down | May 14, 2025 | N/A |
| Dec 31, 2024 | -$0.17 | -$0.09 | N/A | -101.73% | Miss | N/A | N/A | 0 up, 0 down | Mar 26, 2025 | $26274 |
| Sep 30, 2024 | -$0.65 | -$0.48 | -$0.70 - -$0.06 | -35.42% | Miss | N/A | 3 | 1 up, 0 down | Nov 14, 2024 | N/A |
| Jun 30, 2024 | -$0.66 | -$0.67 | -$0.76 - -$0.58 | +1.49% | Beat | N/A | 2 | 0 up, 0 down | Aug 14, 2024 | N/A |
| Mar 31, 2024 | -$0.73 | -$0.79 | -$0.79 - -$0.79 | +7.59% | Beat | N/A | 1 | 0 up, 0 down | May 15, 2024 | N/A |
| Dec 31, 2023 | -$0.64 | -$0.85 | -$0.92 - -$0.78 | +24.71% | Beat | N/A | 2 | 0 up, 0 down | Mar 27, 2024 | N/A |
| Sep 30, 2023 | -$0.86 | -$1.12 | -$1.12 - -$1.12 | +23.21% | Beat | N/A | 1 | 0 up, 0 down | Nov 14, 2023 | $79569 |
| Jun 30, 2023 | -$1.11 | -$0.92 | -$0.92 - -$0.92 | -20.65% | Miss | N/A | 1 | 0 up, 0 down | Aug 14, 2023 | $116410 |
| Mar 31, 2023 | -$0.96 | -$0.90 | -$0.90 - -$0.84 | -6.67% | Miss | N/A | 2 | 0 up, 0 down | May 16, 2023 | N/A |
| Dec 31, 2022 | -$0.18 | -$0.19 | N/A | +5.26% | Beat | N/A | N/A | 0 up, 0 down | Mar 30, 2023 | N/A |
| Sep 30, 2022 | -$0.18 | -$0.18 | -$0.18 - -$0.18 | 0.00% | In line | N/A | 1 | 0 up, 0 down | Nov 14, 2022 | N/A |
| Jun 30, 2022 | -$0.18 | -$0.19 | -$0.19 - -$0.19 | +5.26% | Beat | N/A | 1 | 0 up, 0 down | Aug 12, 2022 | N/A |
| Mar 31, 2022 | -$0.18 | -$0.17 | -$0.17 - -$0.17 | -5.88% | Miss | N/A | 1 | 0 up, 0 down | May 16, 2022 | $46031 |
| Dec 31, 2021 | -$0.20 | -$0.17 | -$0.17 - -$0.17 | -17.65% | Miss | N/A | 1 | N/A | Mar 31, 2022 | $1944 |
| Sep 30, 2021 | -$0.18 | -$0.14 | -$0.14 - -$0.14 | -28.57% | Miss | N/A | 1 | N/A | Nov 15, 2021 | N/A |
| Jun 30, 2021 | -$0.22 | -$0.38 | -$0.38 - -$0.38 | +42.11% | Beat | N/A | 1 | N/A | Aug 16, 2021 | N/A |
| Mar 31, 2021 | -$0.26 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 17, 2021 | N/A |
| Dec 31, 2020 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | $170416 |
| Sep 30, 2020 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 4, 2020 | N/A |
| Jun 30, 2020 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2020 | N/A |
| Mar 31, 2020 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2020 | N/A |
| Dec 31, 2019 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | $240276 |
| Sep 30, 2019 | -$0.05 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2019 | $124431 |
| Jun 30, 2019 | -$0.15 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Sep 30, 2019 | $166931 |
| Mar 31, 2019 | -$0.29 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jun 29, 2019 | $591102 |
| Dec 31, 2018 | -$0.21 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2019 | $1.35M |
| Sep 30, 2018 | -$0.10 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Oct 16, 2018 | N/A |
| Dec 31, 2017 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2018 | $797399 |
| Dec 31, 2016 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2017 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.48, after -$2.21 the year before. It was -$0.02 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.48 | N/A |
| Dec 31, 2024 | -$2.21 | N/A |
| Dec 31, 2023 | -$3.57 | N/A |
| Dec 31, 2022 | -$0.72 | N/A |
| Dec 31, 2021 | -$0.86 | N/A |
| Dec 31, 2020 | -$0.34 | N/A |
| Dec 31, 2019 | -$0.55 | N/A |
| Dec 31, 2018 | -$0.31 | N/A |
| Dec 31, 2017 | -$0.02 | N/A |
| Dec 31, 2016 | -$0.02 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 4,200 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q2 | Jun 30, 2024 | 4,237 | 6 |
2024Q2 Earnings Call
Opening remarks
Alexander Lobo Investor Relations Good morning, and welcome to Inhibikase Therapeutics' Second Quarter 2024 Financial Results Conference Call and Audio Webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer. On August 14th, Inhibikase issued a press release announcing financial results for the second quarter ended June 30th, 2024. We encourage everyone to read yesterday's press release as well as Inhibikase's quarterly report on Form 10-Q, which has been filed with the SEC. The company's press release and Form 10-Q are also available on Inhibikase's website at inhibikase.com. In addition, this conference call is being webcast through the Investor Relations section of the company's website and will be archived there for future reference. Please note that certain information on today's call is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, August 15th, 2024. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. Information on potential risks and uncertainties are set forth in our most recent public filings with the SEC at sec.gov. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webcast, except as may be required by applicable securities law. With that said, I would like to turn the call over to Dr. Milton Werner. Milton, you may begin.
Milton Werner CEO Thank you, Alex. Thank you everybody for joining us today to review our second quarter 2024 financial results and recent clinical and business updates. We've been very pleased with the strength of our clinical progress through the first half of 2024. The speed at which we executed on key clinical and regulatory milestones has underscored what has been a very successful quarter marked by the accomplishment of many exciting achievements. We recently completed an enrollment for our Phase 2 201 trial for risvodetinib, often referred to as risvo, in Parkinson's disease, which is a significant milestone that we have been working tirelessly towards in an effort to bring risvo to patients suffering from untreated Parkinson's disease, and we expect to report top-line data from the trial in November. Additionally, we have had a productive engagement with the US FDA over the past few months regarding IkT-001Pro's opportunity in pulmonary arterial hypertension or PAH.
Frequently Asked Questions About IKT
When is Inhibikase Therapeutics's next earnings date?
Inhibikase Therapeutics's next earnings report is expected for Mar 24, 2027.
Did IKT beat earnings estimates last quarter?
Yes. Inhibikase Therapeutics reported EPS of -$0.10 for the quarter ended Sep 30, 2026, above the -$0.11 estimate, a 9.09% surprise.
What EPS do analysts expect from IKT next quarter?
The consensus EPS estimate for Inhibikase Therapeutics for the quarter ending Dec 31, 2026 is -$0.11 from 10 analysts, with estimates from -$0.16 to -$0.06.
How often does IKT beat earnings estimates?
Inhibikase Therapeutics beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -24.96%.
IKT pages: Overview, Earnings, Forecast, Financials, Competitors